Global specialty plastics provider Eastman demonstrates the dominant performance of next-generation material Eastman MXF221 copolyester as a disinfectant-ready polymer for safer healthcare environments at the Medical Design & Manufacturing (MD&M) West trade show in Anaheim, California, Feb. 6 to 8. The latest advancement in biocompatible medical-grade polymers for medical device housings and hardware, Eastman MXF221 offers unsurpassed chemical compatibility with stringent disinfectants used to combat healthcare-associated infections (HAIs) as well as improved durability and impact strength.
To view the multimedia release go to:
https://www.multivu.com/players/English/8261151-eastman-disinfectant-ready-polymer-mdm-west/
Medical, health, technology, healthcare, treatment, Richard Fechter, interview, trade show, MultiVu 8261151
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, will launch its latest advancement in comprehensive medication management, BD HealthSight™ platform for enterprise medication management, which offers a unique combination of connective technologies, analytics and expert services at this year's American Society of Health-System Pharmacists (ASHP) 2017 Midyear Meeting being held in Orlando from Dec. 3-7.
With direct medical costs associated with medication errors reaching $21 billion worldwide, innovative strategies must be developed to address the grand health challenges associated with medication management. BD has been evolving its focus to re-invent medication management with integration of the company’s technologies, analytics and expert services that aim to close the communication gaps across disparate solutions. The BD HealthSight platform connects systems and processes to help hospitals and health systems drive a safer, more efficient medication management process.
To view the multimedia release go to:
https://www.multivu.com/players/English/8198551-bd-healthsight-platform-ashp-2017/
USANA Health Sciences is pleased to announce an innovative technological advancement: its U.S. patent-pending USANA InCelligence Technology™. This exclusive cell-signaling technology—now found in various USANA® products—is designed to help your body’s cells renew and protect themselves in unique and powerful ways, representing a monumental leap forward in cellular nutrition and overall wellness.*
“USANA continues to build a reputation as an innovator in the science of cellular health and nutritional supplementation,” says USANA Founder Dr. Myron Wentz. “With USANA’s InCelligence Technology, we are ensuring that our company remains on the cutting-edge of nutritional supplementation.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7736551-usana-incelligence-technology/
Modern technology is an amazing thing. We’ve been able to land a probe on Mars. We can clone animals. We have self-driving cars. There have been significant technological advancements in the past decade, but many people see workplace technology lagging behind.
Vonage’s new marketing campaign, “It’s About Time,” illustrates how Vonage is bridging this gap by providing modern, adaptive and intuitive communications solutions that enable businesses to communicate faster, better and smarter. To bring the campaign message to life, Vonage (NYSE: VG) executed a technology takeover at an office building in Atlanta.
To view the multimedia release go to:
http://www.multivu.com/players/English/7872651-vonage-business-tech-takeover/
JNA (Jewellery News Asia), organiser of the prestigious JNA Awards, announces the list of Honourees/finalists across 10 categories at a press conference today held on the sidelines of the June Hong Kong Jewellery & Gem Fair.
The JNA Awards, now in its fifth year, is a premier awards programme that recognises and celebrates excellence and achievement in the jewellery and gemstone industry, with a focus on the advancement of the trade in Asia.
This year, 39 Honourees representing 28 companies from 10 countries/regions, namely Mainland China, Hong Kong, India, Malaysia, Singapore, Switzerland, Taiwan, Thailand, the United Arab Emirates and Vietnam, were selected. A third of these finalists were either first-time entrants or Honourees.
To view the multimedia release go to:
http://www.multivu.com/players/English/7864851-jna-awards-2016/
Walt Disney Records is set to release a new hologram vinyl version of the original motion picture soundtrack for Star Wars: The Force Awakens. With score conducted and composed by five-time Academy Award®-winning composer John Williams and liner notes by the film’s director, J.J. Abrams, the double LP features a 16-page booklet on 180 gram vinyl. This one-of-a-kind vinyl set, hand etched by Tristan Duke (Jack White’s Lazaretto) of Infinity Light Science, offers a 3D hologram experience featuring the Millennium Falcon on Disc 1/Side B and a TIE Fighter on Disc 2/Side B. For optimal viewing, use a direct light source or simply hold a mobile phone flashlight above the vinyl to view the holograms.
Tristan Duke founded Infinity Light Science in 2008, a research laboratory with an emphasis on laser holography, interferometry, light-field imaging, hand-drawn holography, and relativistic imaging.
The must-have vinyl album also features Direct Metal Mastering (DMM) for an optimal listening experience. Disney Music Group has joined forces with Pro-Ject Audio Systems to showcase this unique, next-level advancement in holographic vinyl technology with the Elemental turntable, a combination of minimalist design and maximum performance from the world leader in high fidelity turntables. The two brands will collaborate on co-promotions at retail, online, and radio.
To view the multimedia release go to:
http://www.multivu.com/players/English/7847351-star-wars-the-force-awakens-vinyl/
Leveraging advanced skincare science inspired by the Nobel Prize-winning discovery of Aquaporins, the Artistry Hydra-V™ collection presents a new level of skincare targeting deep hydration. This comprehensive line provides up to 24-hour hydration for skin that feels soft, smooth and supple.
Whatever level of hydration skin needs, the Artistry Hydra-V™ line answers with a range of formulas that can be customized to skin type, season and climate. “Artistry Hydra-V™ products are for the younger consumer who is not yet concerned with the signs of aging but instead want skincare products to give her a beautiful, healthy complexion. This advancement in skincare technology epitomizes the Artistry® Forward Beauty platform and meets the balanced hydration needs of women younger than 35,” says Jackie Nickel, Chief Marketing Officer for the Americas Region. “It’s our first collection to focus on deep hydration for all skin types.”
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7488157-amway-artistry-hydra-v/
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
Adlens, the global leader in adjustable focus eyewear, has launched its ground-breaking adjustable prescription eyewear ‘AdlensFocuss™’, the greatest advancement in optics in more than 50 years.
Vision inevitably changes with age and people often need different strength glasses to see at near, intermediate and far distances. Progressive lenses are an option but they have a restricted usable lens area. A GFK Roper Study has shown one-third of wearers say they have trouble adjusting to them with seven to eight percent of wearers saying they cannot adjust to them at all.
AdlensFocuss provides the benefits of a single vision lens – full frame viewing area – with the best features of a progressive lens – the ability to see at different distances. They are prescription glasses with proprietary technology; a unique flexible membrane that allows the power to be adjusted by simply turning small dials on the inside of the frames. AdlensFocuss lenses offer at least four times more viewing area than traditional progressive lenses and come encased in a fashion-forward frame from award-winning designer Blake Kuwahara.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7544851-adlensfocuss-optics-technology/
ACCU-CHEK Aviva Expert offers people with diabetes a new and easy way to simplify complex calculations to deliver precise insulin dosing advice.
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the ACCU-CHEK® Aviva Expert system, the first and only blood glucose meter system with a built-in insulin calculator to be approved by the U.S. Food and Drug Administration (FDA), is now available by prescription. The device represents a significant advancement in blood glucose meter technology for people with diabetes who take multiple daily insulin injections. The meter’s integrated bolus calculator provides easy-to-use and reliable dose recommendations based on automated calculations, eliminating the need for manual dosing calculations and estimations.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7322751-roche-accu-chek-aviva-expert-blood-glucose-meter-now-available/
